Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322732 | 0.93 | MAPT (0.43) | MAPTL3MBTL1LMNAKDM4EKDM1A | |
| SCHEMBL6853104 | 0.92 | TUBB4A (0.50) | MAPTL3MBTL1LMNAKDM4EKDM1A | |
| SCHEMBL6861039 | 0.91 | MAPT (0.40) | MAPTL3MBTL1LMNAKDM4EKDM1A | |
| SCHEMBL6315628 | 0.89 | KDM1A (0.42) | MAPTLMNAKDM4EKDM1AHTT | |
| SCHEMBL6322521 | 0.88 | MAPT (0.40) | MAPTL3MBTL1LMNAKDM4EKDM1A | |
| SCHEMBL6316242 | 0.88 | MAPT (0.45) | MAPTL3MBTL1LMNAKDM4EKDM1A | |
| SCHEMBL7115907 | 0.87 | MAPT (0.46) | MAPTL3MBTL1LMNAKDM4EKDM1A | |
| SCHEMBL6322457 | 0.85 | MAPT (0.43) | MAPTL3MBTL1LMNAKDM4EKDM1A | |
| SCHEMBL7128967 | 0.85 | MAPT (0.55) | MAPTL3MBTL1LMNAKDM4EKDM1A | |
| SCHEMBL7125958 | 0.85 | TUBB4A (0.48) | MAPTL3MBTL1LMNAKDM4EKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887904-B2 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-05-03 | — | — | US | disclosed |
| EP-1453783-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | Aventis Pharma S.A. (FR) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | US | disclosed |
| WO-2003048096-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | AVENTIS PHARMA S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | ABL1, MCL1, AHR | MAPT 4538/4885L3MBTL1 3439/4885LMNA 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.